|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 1. |
(WO 2007/147122) MONOCLONAL ANTIBODIES THAT SELECTIVELY RECOGNIZE METHAMPHETAMINE AND METHAMPHETAMINE LIKE COMPOUNDS
|
21.12.2007
|
C07K 16/00
|
PCT/US2007/071354
|
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
|
| |
The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (-) methamphetamine, (-) amphetamine, or (-) MDMA.
|
| |
|
| 2. |
(WO 2007/147105) ROBUST OBJECT TRACKING SYSTEM
|
21.12.2007
|
No IPC Found |
PCT/US2007/071320
|
OMRON CORPORATION
|
| |
A method for tracking objects includes identifying a target, identifying a plurality of auxiliary objects related to the target, and tracking the target using the plurality of auxiliary objects.
|
| |
|
| 3. |
(WO 2007/147098) IDENTIFICATION AND USE OF NON-PEPTIDE ANALOGS OF RNAIII-INHIBITING PEPTIDE FOR THE TREATMENT OF STAPHYLOCOCCAL INFECTIONS
|
21.12.2007
|
A01N 43/08
|
PCT/US2007/071303
|
TUFTS UNIVERSITY
|
| |
RNAIII inhibiting peptide (RIP) has been established as an effective inhibitor of staphylococcal infections. Non-peptide small molecule analogs based on a pharmacophore conforming to the putative atomic structure of RIP, can be identified by computer screening of that pharmacophore against established libraries of known small molecules other than peptides. One such identified structural analog is hamamelitannin. When tested for effective inhibition of staphylococcal infections, hamamelitannin demonstrated inhibition similar to that exhibited by RIP. Other analogs can be identified and similarly used.
|
| |
|
| 4. |
(WO 2007/147097) FLUID TREATMENT USING PLASMA TECHNOLOGY
|
21.12.2007
|
C02F 1/46
|
PCT/US2007/071302
|
DREXEL UNIVERSITY
|
| |
A method for the treatment of fluid including the step of exposing the fluid to a pulsed plasma discharge. The pulsed plasma discharge will be generated using a suitable electrode configuration to generate the plasma discharge in the fluid. Apparatus useful in the method may include a vessel, at least two electrodes for generating a plasma discharge in water, and a flow inlet and a flow outlet to allow water to be passed through the vessel. Also described is an in-line water treatment, where a pulsed plasma discharge is used in a pipe carrying moving water. Plasma based fluid treatment system may have many advantages in comparison to other treatment methods, such as very minimal maintenance, low operating power, and minimal pressure loss th...
|
| |
|
| 5. |
(WO 2007/147087) ADSORPTION-RESISTANT ACRYLIC COPOLYMER FOR FLUIDIC DEVICES
|
21.12.2007
|
C08F 2/00
|
PCT/US2007/071266
|
BRIGHAM YOUNG UNIVERSITY
|
| |
A copolymer is used for fluidic devices that require surfaces nonreactive with biomolecules. The copolymer is the reaction product of Compound (A) having the formula: and Compound (B) having the formula where the R groups are the same or different and are selected from hydrogen, and alkyl groups with 4 carbons or less, where n is the same or different and is greater than 3.
|
| |
|
| 6. |
(WO 2007/147086) ADSORPTION-RESISTANT ACRYLIC COPOLYMER FOR FLUIDIC DEVICES
|
21.12.2007
|
B32B 27/20
|
PCT/US2007/071264
|
BRIGHAM YOUNG UNIVERSITY
|
| |
A copolymer is used for fluidic devices that require surfaces nonreactive with biomolecules. The copolymer is the reaction product of Compound (A) having the formula: and Compound (B) having the formula: where the R groups are the same or different and are selected from hydrogen, and alkyl groups with 4 carbons or less, where n is the same or different and is greater than 3.
|
| |
|
| 7. |
(WO 2007/147057) DEVICES FOR ADJUSTABLE, KNOTLESS TISSUE APPROXIMATION
|
21.12.2007
|
A61B 17/04
|
PCT/US2007/071220
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
Devices and methods for tissue approximation and distribution of tissue stresses and tension resulting therefrom. The devices comprise a shank having one or more structures thereon, an anchor button fixedly attached to one end of the shank with the opposite end of the shank being suitable for penetration of tissues or other structures. To secure the device, the shank engages with a locking button having a locking mechanism thereon. The locking button is engaged with the shank, preferably after a tissue approximation, so that the locking button can be advanced along the shank towards the anchor button compressing the approximated tissues between the anchor button and the locking button.
|
| |
|
| 8. |
(WO 2007/147013) COMBINED MEMBRANE-DISTILLATION-FORWARD-OSMOSIS SYSTEMS AND METHODS OF USE
|
21.12.2007
|
C02F 1/44
|
PCT/US2007/071141
|
BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
|
| |
In some embodiments, systems and methods are provided for purifying a liquid, such as an impaired water. In some examples, seawater or brackish water is purified, such as to a potable level. Some configurations provide a system which includes a membrane-distillation unit, such as a vacuum-enhanced direct contact membrane distillation unit. The system also includes a forward-osmosis system, which may include one or more forward-osmosis units. A concentrated draw stream from the membrane-distillation unit, such as a concentrated brine solution, serves as a draw solution for a forward-osmosis unit, which may extract water from a source water, such as an impaired water. In some implementations, the forward-osmosis system includes a second forwa...
|
| |
|
| 9. |
(WO 2007/146988) METHODS OF DIMINISHING PERMANENT TISSUE MARKINGS AND RELATED APPARATUS
|
21.12.2007
|
A61N 7/00
|
PCT/US2007/071088
|
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
|
| |
A method of diminishing permanent tissue markings on a person caused by particles in the dermis includes applying ultrasound radiation to the tissue to generate cavitation bubbles and altering the tissue marking particles by collapse of the cavitation bubbles and transferring energy to the particles. The ultrasound radiation in one embodiment may have a frequency of about 15 KHz to 2 MHz and may be pulsed. The process may be repeated at the same location or other locations while resisting undesired, excessive bleeding of the dermis. The permanent tissue markings may be tattoos. The method may be used in conjunction with other methods of removing the permanent tissue markings, which may include laser, chemical agents, and biological agents. ...
|
| |
|
| 10. |
(WO 2007/146948) METHOD, SYSTEM AND SOFWARE ARRANGEMENT FOR DETERMINING AN INTERACTION BETWEEN AN ELECTROMAGNETIC RADIATION AND A MATERIAL
|
21.12.2007
|
G01J 3/30
|
PCT/US2007/071018
|
NEW YORK UNIVERSITY
|
| |
The exemplary embodiments of the method, system, software arrangement and computer- accessible medium according to the present invention facilitates an analysis of interactions between nonlinear absorbing materials and an incident (e.g., coherent) electromagnetic wave based on material properties and characteristics of the incident beam of the electromagnetic energy. For example, using the exemplary embodiments of the present invention, it is possible to determine a laser beam propagation in a variety of multiphoton absorbing materials. Energy levels associated with such materials, which may be associated with various electron absorption and/or relaxation phenomena, may be added to and/or removed from the analysis.. Incident laser beams can...
|
| |
|
| 11. |
(WO 2007/146938) APPARATUS AND METHOD FOR DEEP ULTRAVIOLET OPTICAL MICROSCOPY
|
21.12.2007
|
G02B 21/00
|
PCT/US2007/071003
|
INVENT TECHNOLOGIES LLC
|
| |
An apparatus and method for performing optical microscopy are disclosed. In at least one embodiment, the apparatus includes a deep ultraviolet light source configured to generate light having a wavelength within a window in the deep ultraviolet region of the electromagnetic spectrum within which a local minimum in the absorption coefficient of Oxygen occurs. Further, the apparatus includes a lens device that receives at least a first portion of the generated light, directs at least some of the first portion of the generated light toward a location, receives reflected light from the location, and directs at least some of the reflected light toward a further location. Additionally, the apparatus includes a camera device that is positioned at ...
|
| |
|
| 12. |
(WO 2007/146897) THE TREATMENT OF XEROSTOMIA
|
21.12.2007
|
A61K 38/30
|
PCT/US2007/070924
|
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
|
| |
Methods for the treatment of xerostomia are described, hi particular, the present invention takes advantage of the inventors' observation that xerostomia is caused by induction of apoptosis, and can be inhibited by interfering with the cellular processes that trigger apoptosis in cells receiving chemo- and/or radiotherapy.
|
| |
|
| 13. |
(WO 2007/146883) METHODS FOR ASSESSING CANCER SUSCEPTIBILITY TO CARCINOGENS IN TOBACCO PRODUCTS
|
21.12.2007
|
G01N 33/567
|
PCT/US2007/070891
|
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
|
| |
The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease.
|
| |
|
| 14. |
(WO 2007/146847) GLYCOSYLATION ENGINEERED ANTIBODY THERAPY
|
21.12.2007
|
A61K 39/00
|
PCT/US2007/070818
|
UNIVERSITY OF MARYLAND, BALTIMORE
|
| |
The instant invention is drawn to methods of generating a glycosylation- engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation- engineered antibody.
|
| |
|
| 15. |
(WO 2007/146841) COLLAGEN CROSS-LINKING AGENTS ON DENTAL RESTORATIVE TREATMENT AND PREVENTIVE DENTISTRY
|
21.12.2007
|
A61K 31/352
|
PCT/US2007/070809
|
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
|
| |
The invention relates to the development of compositions and methods for increasing the amount of collagen cross-linking in a mammalian tissue. A typical composition as described herein includes at least one cross-linking agent such as a bioflavonoid compound (e.g., proanthocyanidin), a grape seed extract, a Casein Phosphopeptide-amorphous Calcium Phosphate, or an iridoid compound (e.g., genipin) in an amount effective for increasing collagen cross-linking in the mammalian tissue in a pharmaceutically acceptable carrier. A typical method for increasing the amount of collagen cross-linking in dentin in a mammalian tooth includes the steps of preparing the surface of the tooth to be treated; and applying a composition including at least one o...
|
| |
|
| 16. |
(WO 2007/146811) ASSESSMENT OF CELLULAR COMPOSITION AND FRACTIONAL VIABILITY AND USES THEREOF
|
21.12.2007
|
C12N 5/00
|
PCT/US2007/070772
|
UNIVERSITY OF MIAMI
|
| |
A method of assessing cellular composition and fractional viability that can be predictive of post-transplant cell potency and transplantation outcome, comprises identifying cellular composition and assessing cellular viability. This has particular importance in the field of tissue and cell transplantation, cell therapy and regenerative medicine, providing a method for tissue and cell characterization, viability and potency testing, that could be useful for the definition of product release criteria for research and clinical applications.
|
| |
|
| 17. |
(WO 2007/146802) SYSTEM AND COMPOSITIONS FOR ISOLATING SUPPRESSORS OF HIV-1 PROTEASE
|
21.12.2007
|
C12Q 1/37
|
PCT/US2007/070757
|
UNIVERSITY OF MARYLAND, BALTIMORE
|
| |
The present invention relates to a yeast screening assay for the identification of suppressors of a protease, such as the HIV-I protease and/or HIV-2 protease, for example. Upon overexpression of HIV-I protease in Schizosaccharomyces pombe, for example, the cell dies, but in the presence of a candidate inhibitor with protease suppressor activity, the cell lives, thereby providing an assay for the identification of one or more suppressors. In additional aspects, there is an in vivo protease activity screen, used alternatively or additionally to a viability screen, such as for cleavage of a HIV-I protease-specific site. In further aspects, the suppressor is employed for the treatment of an individual infected with HIV virus or with AIDS.
|
| |
|
| 18. |
(WO 2007/146796) ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
|
21.12.2007
|
C07C 69/003
|
PCT/US2007/070747
|
RAMOT AT TEL-AVIV UNIVERSITY LTD.
|
| |
The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6, C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2NR7R8. Also provided is a pharmaceutical composition that includes on...
|
| |
|
| 19. |
(WO 2007/146750) PAS KINASE REGULATES ENERGY HOMEOSTASIS
|
21.12.2007
|
C12N 9/12
|
PCT/US2007/070641
|
UNIVERSITY OF UTAH RESEARCH FOUNDATION
|
| |
Disclosed are compositions and methods related to PAS Kinase (PASK) and various diseases and disorders associated therewith. Included are methods for treating insulin resistance, cancer, and diabetes comprising administering a composition that inhibits PAS Kinase. Further included are methods, including high throughput screening methods, for identifying test compounds that modulate PAS Kinase.
|
| |
|
| 20. |
(WO 2007/146747) PAS KINASE REGULATES ENERGY HOMEOSTASIS
|
21.12.2007
|
A61K 31/53
|
PCT/US2007/070634
|
UNIVERSITY OF UTAH RESEARCH FOUNDATION
|
| |
Disclosed are compositions and methods related to PAS Kinase and various diseases and disorders associated therewith. Included are methods for treating insulin resistance, cancer, and diabetes comprising administering a composition that inhibits PAS Kinase and methods, including high throughput screening methods, for identifying test compounds that modulate PAS Kinase.
|
| |
|
| 21. |
(WO 2007/146706) MODIFIED DICAMBA MONOOXYGENASE ENZYME AND METHODS OF ITS USE
|
21.12.2007
|
C12N 15/82
|
PCT/US2007/070514
|
MONSANTO TECHNOLOGY LLC
|
| |
The invention provides a modified variant of dicamba monooxygenase (DMO). The invention relates to the unexpected finding that cells expressing this DMO exhibit high levels of tolerance to the herbicide dicamba. Compositions comprising DMO-encoding nucleic acids and methods of use are provided.
|
| |
|
| 22. |
(WO 2007/146680) STABILIZED SILICA COLLOID
|
21.12.2007
|
B32B 5/16
|
PCT/US2007/070443
|
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION , INC.
|
| |
A nanoparticle has at least one dimension less than 500 nm and comprises a silica surface and a plurality of zwitterionic functional groups covalently bound to the silica surface. Such nanoparticles and dispersions contain such nanoparticle are prepared and used for a variety of purposes.
|
| |
|
| 23. |
(WO 2007/146668) USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER
|
21.12.2007
|
G01N 1/00
|
PCT/US2007/070412
|
UNIVERSITY OF MASSACHUSETTS
|
| |
Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but alos can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
|
| |
|
| 24. |
(WO 2007/146427) METHOD FOR TREATING DIABETIC VASCULAR COMPLICATIONS
|
21.12.2007
|
A61K 36/00
|
PCT/US2007/014089
|
NATIONAL YANG-MING UNIVERSITY
|
| |
The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.
|
| |
|
| 25. |
(WO 2007/146422) ELECTRIC MACHINERY LAMINATED CORES WITH INSULATING LAMINATIONS
|
21.12.2007
|
H02K 1/00
|
PCT/US2007/014068
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
Embodiments of the present invention provide methods and insulated laminate cores to be used in electric machines (201). A laminated core (203, 211), for example, includes a plurality of electrical steel laminations (205) defining a lamination stack having a core length and one or more insulating laminates interspersed along the core length to thereby reduce stack length and reduce eddy current.
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
